Opko Acquires CLIA Lab | GenomeWeb

NEW YORK (GenomeWeb News) – Opko Health has acquired Prost-Data, a Nashville, Tenn.-based CLIA laboratory doing business under the name OURLab.

Opko said that the acquisition would provide it with a commercial platform to support the US commercial launch of its 4Kscore protein biomarker prostate cancer test. The 4kscore test employs two protein biomarkers in the kallikrein family along with prostate-specific antigen for early detection of prostate cancer.

The lab has 18 phlebotomy sites throughout the US and a national sales force calling on urologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: system to track intron gains and losses, role of RUNX during mitosis, and more.

French officials release a report and move to strength safety measures for clinical trials, ScienceInsider reports.

Researchers find different molecular signatures in cancers from men as compared to those from women, the Wall Street Journal reports.

Researchers trace the deaths of a pair of newborn siblings to a mutation in their LIPT1 genes through whole-exome sequencing, Stat News reports.